116 related articles for article (PubMed ID: 35617527)
41. Malawi pilot study of Burkitt lymphoma treatment.
Hesseling PB; Broadhead R; Molyneux E; Borgstein E; Schneider JW; Louw M; Mansvelt EP; Wessels G
Med Pediatr Oncol; 2003 Dec; 41(6):532-40. PubMed ID: 14595710
[TBL] [Abstract][Full Text] [Related]
42. Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China.
Jia M; Hu BF; Xu XJ; Zhang JY; Li SS; Tang YM
Curr Probl Cancer; 2021 Dec; 45(6):100758. PubMed ID: 34034913
[TBL] [Abstract][Full Text] [Related]
43. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.
Hoffmann C; Wolf E; Wyen C; Fätkenheuer G; Van Lunzen J; Stellbrink HJ; Stoehr A; Plettenberg A; Jaeger H; Noppeney R; Hentrich M; Goekbuget N; Hoelzer D; Horst HA
Leuk Lymphoma; 2006 Sep; 47(9):1872-80. PubMed ID: 17065000
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels.
Kim HD; Cho H; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Kim SJ; Ko YH; Kim WS; Suh C
Cancer Res Treat; 2021 Jul; 53(3):847-856. PubMed ID: 33332932
[TBL] [Abstract][Full Text] [Related]
45. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
Yang ZJ; Wei RJ; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
[TBL] [Abstract][Full Text] [Related]
46. Metabolic path toward TCF3 inactivation in Burkitt lymphoma.
Klein U
Blood; 2022 Jan; 139(4):475-476. PubMed ID: 35084477
[No Abstract] [Full Text] [Related]
47. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
Miralles P; Berenguer J; Ribera JM; Rubio R; Mahillo B; Téllez MJ; Lacruz J; Valencia E; Santos J; Rodríguez-Arrondo F; Pintado V;
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):167-73. PubMed ID: 17117144
[TBL] [Abstract][Full Text] [Related]
48. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
[TBL] [Abstract][Full Text] [Related]
49. [Clinical Features and Prognosis of 35 Children with Burkitt Lymphoma/Leukemia].
Zheng YZ; LE SH; Zheng H; Hua XL; Chen ZS; Zheng L; Chen C; Li M; Cai CX; Yang JH; Chen YQ; Gao QL; Chen YY; Li J; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1123-1130. PubMed ID: 31418367
[TBL] [Abstract][Full Text] [Related]
50. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
Pillon M; Di Tullio MT; Garaventa A; Cesaro S; Putti MC; Favre C; Lippi A; Surico G; Di Cataldo A; D'Amore E; Zanesco L; Rosolen A
Cancer; 2004 Jul; 101(2):385-94. PubMed ID: 15241838
[TBL] [Abstract][Full Text] [Related]
51. Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma.
Nomura Y; Yoshida S; Karube K; Takeshita M; Hirose S; Nakamura S; Yoshino T; Kikuchi M; Ohshima K
Cancer Sci; 2008 Aug; 99(8):1564-9. PubMed ID: 18754867
[TBL] [Abstract][Full Text] [Related]
52. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
53. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults.
Magrath IT; Janus C; Edwards BK; Spiegel R; Jaffe ES; Berard CW; Miliauskas J; Morris K; Barnwell R
Blood; 1984 May; 63(5):1102-11. PubMed ID: 6546890
[TBL] [Abstract][Full Text] [Related]
54. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia.
Miles RR; Arnold S; Cairo MS
Br J Haematol; 2012 Mar; 156(6):730-43. PubMed ID: 22260323
[TBL] [Abstract][Full Text] [Related]
55. [Effect of Modified LMB 89± Rituximab Regimen on Long-Term Benefits for Patients's with Burkitt Lymphoma].
Tan L; Xie Y; Yang J; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):872-875. PubMed ID: 32552950
[TBL] [Abstract][Full Text] [Related]
56. The increased expression of TCF3 is correlated with poor prognosis in Chinese patients with nasopharyngeal carcinoma.
Shen X; Yuan J; Zhang M; Li W; Ni B; Wu Y; Jiang L; Fan W; Tian Z
Clin Otolaryngol; 2017 Aug; 42(4):824-830. PubMed ID: 28107608
[TBL] [Abstract][Full Text] [Related]
57. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Schmitz R; Young RM; Ceribelli M; Jhavar S; Xiao W; Zhang M; Wright G; Shaffer AL; Hodson DJ; Buras E; Liu X; Powell J; Yang Y; Xu W; Zhao H; Kohlhammer H; Rosenwald A; Kluin P; Müller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Ogwang MD; Reynolds SJ; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pittaluga S; Wilson W; Waldmann TA; Rowe M; Mbulaiteye SM; Rickinson AB; Staudt LM
Nature; 2012 Oct; 490(7418):116-20. PubMed ID: 22885699
[TBL] [Abstract][Full Text] [Related]
58. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia.
Todeschini G; Bonifacio M; Tecchio C; Balter R; Carli G; Stefani PM; Adami F; Zamò A; Dei Tos AP; Marino F; Gherlinzoni F; Marradi P; Semenzato G; Pizzolo G
Am J Hematol; 2012 Jan; 87(1):22-5. PubMed ID: 22086870
[TBL] [Abstract][Full Text] [Related]
59. Value of baseline and end of chemotherapy
Xiao Z; Mo Y; Long W; Li R; Li X; Wei Y; Fan W; Zhang X
Leuk Lymphoma; 2021 Dec; 62(12):2873-2881. PubMed ID: 34165390
[TBL] [Abstract][Full Text] [Related]
60. FAB LMB 96 Regimen for Newly Diagnosed Burkitt Lymphoma in Children: Single-center Experience.
Aydin B; Akyuz C; Kalkan N; Kurucu N; Varan A; Yalcin B; Kutluk T
J Pediatr Hematol Oncol; 2019 Jan; 41(1):e7-e11. PubMed ID: 30059355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]